EXPLORANCE
1.10.2018 07:02:05 CEST | Business Wire | Press release
Explorance, the leading provider of Learning Journey Analytics (LJA) solutions doubled its European client base in the past year. With the opening of new European offices, Explorance will be able to better partner with its growing European clients.
Improving the quality and relevance of teaching and learning in the European higher education market is the centre of the Bologna Process. The Yerevan Communiqué strengthened the call for better visibility of this policy area. According to the EUA Trends 2018 survey, 90% of the institutions use student feedback surveys to assess and enhance the quality of teaching. As the Bologna Process entices institutions to embrace a digitally-enabled approach, more institutions move toward the strategic use of digital tools to measure learning and teaching improvements.
“Before implementing Blue, we were using a dozen or so traditional questionnaires, combined with a few digital surveys. The wide range of individual solutions made it impossible to take full benefit of course evaluations,” says Mustapha Ali El-Ahmad, Senior Evaluation Consultant and Analyst at the Aarhus University. He adds, “Blue combines all these different questionnaires into one single solution, cleaning the data from the LMS & SIS, and automating the data analysis, while accommodating to different schools’ requirements.” Explorance’s Blue is built to support various feedback processes including course evaluations, competency development assessment, midterm reviews, applicant feedback, alumni perception analysis, student satisfaction, organisational surveys, and 360 degree reviews.
“The surge in demand for Explorance software and services in Europe indicates a growing need for proven online teaching and learning evaluation tools and increased trust in the Blue solution,” commented Ian Haugh, General Manager of the European offices. The new European office is located in Amsterdam and coordinates local activities across Europe and the UK. Local professional services are offered across Europe and customer service is provided 24/7 in multiple languages.
Blue surveys and evaluation solutions are fully localised with English, French, Spanish, German, Dutch, Swedish, Norwegian, Danish, Icelandic, Italian, Russian and Portuguese support. To support student mobility, Blue allows multiple languages to be used in one implementation at the same time. For an evaluation of your organisation’s needs, contact Explorance for a demonstration .
About Explorance
Explorance is a Learning Journey Analytics (LJA) provider that supports organisations in making the right decisions using fact-based feedback data. Through its Blue suite of products, organisations can assess needs, expectations, competencies, and monitor improvement over time.
Founded in 2003, Explorance is a privately held corporation headquartered in Montreal, Canada with business units in America, APAC, Europe, and the MENA region. As of 2014, Explorance has been ranked top employer by the Great Places to Work Institute®. Explorance's clients span a wide variety of learning organisations including academia, consulting firms, government institutions, and corporations. Learn more about Explorance .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005020/en/
Contact:
Gil Gruber gil@directobjective.com +1.514.238.7766
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 22:00:00 CEST | Press release
Marks Historic Milestone for U.S. Energy Export Infrastructure under the U.S.-Japan Trade Deal Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom